VALENCIA, SPAIN -- July 05, 2017 -- InvestorsHub NewsWire --
Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a
healthcare technology company primarily focused on the development
and commercialization of MIDS Cardiac™, a Point of Care ("POC")
handheld device for the early detection of certain cardiac event
biomarkers to significantly accelerate the triage, diagnosis,
treatment and disposition of patients reporting chest pain and with
suspected acute myocardial infarction (heart attack), is pleased to
announce that its MIDS Medical Limited joint venture ("MML") based
at Sci-Tech, Daresbury (UK), has commenced testing of its "Hybrid
Strip" system.
The Hybrid Strip is a first iteration simulation of the MML
"MIDS" Lab-on-Chip ("LoC") test strip system, an assembled unit
that replicates, as closely as possible, a fully integrated LoC
system. The Hybrid Strip is designed to prove the principle of LoC
nano-magnetic detection of high sensitivity assay sized quantities
of paramagnetic nanoparticles. It will be used to gather data from
low doses of nanoparticles & microbeads.
The Hybrid Strip consists of a micro machined, plasma coated
plastic strip with a microfluidic channel designed to flow fluid
entrained nanoparticles and microbeads into a magnetic entrapment
and detection area. This was designed by MML in its laboratories at
Sci-Tech, Daresbury in consultation with a European manufacturer
highly experienced and specialized in biomedical microfluidics
manufacturing. This process allowed MML to skip a planned step of
flow simulation prior to production. Flow testing of the produced
microfluidic strip suggests that its channel geometry will perform
to design.
Hall Effect sensors are mounted on a flexible circuit board
bonded to and integrated into the Hybrid Strip so as to locate the
sensors in close proximity to the detection area. A number of these
bonded and plasma coated strips have been produced in-house for the
test program.
A 3D printed magnet holder assembly has also been designed and
delivered to fit the Hybrid Strip. This will produce the precisely
located bias magnetic field necessary to magnetize, move and entrap
the nanoparticles within the Hybrid Strip.
Initially the proven master circuit board, previously used for
testing the original "test slide" system, will be connected to test
the Hybrid Strip. Testing is anticipated to commence this week and
to continue over approximately six weeks.
Should the MIDS nano-magnetic detection system be proven to work
in line with MML's expectations, the Company believes that the MIDS
system will be applicable to POC high sensitivity troponin testing
and a new generation of POC immunoassay tests, previously limited
by optical detection methods.
Carlos Gil, CEO of Zenosense, Inc.,
commented: "I look forward to this commencement of
testing of the Hybrid Strip. It is an exciting phase of our
development, designed to definitively prove this remarkable, novel
method of detection."
About Zenosense, Inc.
Zenosense Inc.'s primary focus, through our joint venture
ownership in MIDS Medical Ltd., is the development of a
cost-effective, hand-held Point of Care rapid cardiac diagnostic
device, MIDS Cardiac™, and is also the holder of an exclusive
global license agreement to develop and market effective medical
devices for use in hospitals and primary healthcare settings
targeting the early detection of both deadly bacteria and certain
cancers in the exhaled breath of patients.
To find out more about Zenosense (OTC PINK: ZENO), visit our website
at www.zenosense.com.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements can
often be identified by words such as "expects," "intends," "plans,"
"may," "could," "should," "anticipates," "likely," "believes" and
words of similar import. Forward-looking statements are based on
current facts and analyses and other information that are based on
forecasts of future results, estimates of amounts not yet
determined and assumptions of management. Actual results may differ
materially from those expressed or implied by forward-looking
statements due to a variety of factors that may or may not be
foreseeable or within the reasonable control of the Company.
Readers are cautioned not to place undue reliance on such
forward-looking statements. Additional information on risks and
other factors that may affect the business and financial results of
the Company can be found in filings of the Company with the U.S.
Securities and Exchange Commission, including without limitation
the section entitled "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2016 filed on filed on
April 17, 2017, and in Company reports filed subsequently thereto.
Except as otherwise required by law, the Company disclaims any
obligations or undertaking to publicly release any updates or
revisions to any forward-looking statement contained in this news
release to reflect any change in the Company's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statement is based. Respective statements
concerning the development of both MIDS Cardiac™ and other devices
under development have been made based on information obtained from
MIDS Medical Ltd. and Zenon Biosystem, which the Company believes
to be accurate, but have not been independently verified.